Targeted correction of RUNX1 mutation in FPD patient-specific induced pluripotent stem cells rescues megakaryopoietic defects

Jon P. Connelly, Erika M. Kwon, Yongxing Gao, Niraj S. Trivedi, Abdel G. Elkahloun, Marshall S. Horwitz, Linzhao Cheng, P. Paul Liu

Research output: Contribution to journalArticle

Abstract

Familial platelet disorder with predisposition to acute myeloid leukemia (FPD/AML) is an autosomaldominant disease of the hematopoietic system that is caused by heterozygous mutations in RUNX1. FPD/AML patients have a bleeding disorder characterized by thrombocytopenia with reduced platelet numbers and functions, and a tendency to develop AML. No suitable animal models exist for FPD/AML, as Runx1+/-mice and zebra fish do not develop bleeding disorders or leukemia. Here we derived induced pluripotent stem cells(iPSCs) from 2 patientsina family with FPD/AML, and found that the FPD iPSCs display defects in megakaryocytic differentiation in vitro. We corrected the RUNX1 mutation in 1 FPD iPSC line through gene targeting, which led to normalization of megakaryopoiesis of the iPSCs in culture. Our results demonstrate successful in vitro modeling of FPD with patient-specific iPSCs and confirm that RUNX1 mutations are responsible for megakaryopoietic defects in FPD patients.

Original languageEnglish (US)
Pages (from-to)1926-1930
Number of pages5
JournalBlood
Volume124
Issue number12
DOIs
StatePublished - Sep 18 2014

Fingerprint

Induced Pluripotent Stem Cells
Platelets
Stem cells
Acute Myeloid Leukemia
Blood Platelets
Defects
Mutation
Hemorrhage
Hematopoietic System
Gene Targeting
Zebrafish
Platelet Count
Cell culture
Thrombocytopenia
Fish
Leukemia
Animals
Animal Models
Cell Culture Techniques
Genes

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Connelly, J. P., Kwon, E. M., Gao, Y., Trivedi, N. S., Elkahloun, A. G., Horwitz, M. S., ... Liu, P. P. (2014). Targeted correction of RUNX1 mutation in FPD patient-specific induced pluripotent stem cells rescues megakaryopoietic defects. Blood, 124(12), 1926-1930. https://doi.org/10.1182/blood-2014-01-550525

Targeted correction of RUNX1 mutation in FPD patient-specific induced pluripotent stem cells rescues megakaryopoietic defects. / Connelly, Jon P.; Kwon, Erika M.; Gao, Yongxing; Trivedi, Niraj S.; Elkahloun, Abdel G.; Horwitz, Marshall S.; Cheng, Linzhao; Liu, P. Paul.

In: Blood, Vol. 124, No. 12, 18.09.2014, p. 1926-1930.

Research output: Contribution to journalArticle

Connelly, JP, Kwon, EM, Gao, Y, Trivedi, NS, Elkahloun, AG, Horwitz, MS, Cheng, L & Liu, PP 2014, 'Targeted correction of RUNX1 mutation in FPD patient-specific induced pluripotent stem cells rescues megakaryopoietic defects', Blood, vol. 124, no. 12, pp. 1926-1930. https://doi.org/10.1182/blood-2014-01-550525
Connelly, Jon P. ; Kwon, Erika M. ; Gao, Yongxing ; Trivedi, Niraj S. ; Elkahloun, Abdel G. ; Horwitz, Marshall S. ; Cheng, Linzhao ; Liu, P. Paul. / Targeted correction of RUNX1 mutation in FPD patient-specific induced pluripotent stem cells rescues megakaryopoietic defects. In: Blood. 2014 ; Vol. 124, No. 12. pp. 1926-1930.
@article{5b7fc02d1b414c0a9f1f03befdbf11c3,
title = "Targeted correction of RUNX1 mutation in FPD patient-specific induced pluripotent stem cells rescues megakaryopoietic defects",
abstract = "Familial platelet disorder with predisposition to acute myeloid leukemia (FPD/AML) is an autosomaldominant disease of the hematopoietic system that is caused by heterozygous mutations in RUNX1. FPD/AML patients have a bleeding disorder characterized by thrombocytopenia with reduced platelet numbers and functions, and a tendency to develop AML. No suitable animal models exist for FPD/AML, as Runx1+/-mice and zebra fish do not develop bleeding disorders or leukemia. Here we derived induced pluripotent stem cells(iPSCs) from 2 patientsina family with FPD/AML, and found that the FPD iPSCs display defects in megakaryocytic differentiation in vitro. We corrected the RUNX1 mutation in 1 FPD iPSC line through gene targeting, which led to normalization of megakaryopoiesis of the iPSCs in culture. Our results demonstrate successful in vitro modeling of FPD with patient-specific iPSCs and confirm that RUNX1 mutations are responsible for megakaryopoietic defects in FPD patients.",
author = "Connelly, {Jon P.} and Kwon, {Erika M.} and Yongxing Gao and Trivedi, {Niraj S.} and Elkahloun, {Abdel G.} and Horwitz, {Marshall S.} and Linzhao Cheng and Liu, {P. Paul}",
year = "2014",
month = "9",
day = "18",
doi = "10.1182/blood-2014-01-550525",
language = "English (US)",
volume = "124",
pages = "1926--1930",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "12",

}

TY - JOUR

T1 - Targeted correction of RUNX1 mutation in FPD patient-specific induced pluripotent stem cells rescues megakaryopoietic defects

AU - Connelly, Jon P.

AU - Kwon, Erika M.

AU - Gao, Yongxing

AU - Trivedi, Niraj S.

AU - Elkahloun, Abdel G.

AU - Horwitz, Marshall S.

AU - Cheng, Linzhao

AU - Liu, P. Paul

PY - 2014/9/18

Y1 - 2014/9/18

N2 - Familial platelet disorder with predisposition to acute myeloid leukemia (FPD/AML) is an autosomaldominant disease of the hematopoietic system that is caused by heterozygous mutations in RUNX1. FPD/AML patients have a bleeding disorder characterized by thrombocytopenia with reduced platelet numbers and functions, and a tendency to develop AML. No suitable animal models exist for FPD/AML, as Runx1+/-mice and zebra fish do not develop bleeding disorders or leukemia. Here we derived induced pluripotent stem cells(iPSCs) from 2 patientsina family with FPD/AML, and found that the FPD iPSCs display defects in megakaryocytic differentiation in vitro. We corrected the RUNX1 mutation in 1 FPD iPSC line through gene targeting, which led to normalization of megakaryopoiesis of the iPSCs in culture. Our results demonstrate successful in vitro modeling of FPD with patient-specific iPSCs and confirm that RUNX1 mutations are responsible for megakaryopoietic defects in FPD patients.

AB - Familial platelet disorder with predisposition to acute myeloid leukemia (FPD/AML) is an autosomaldominant disease of the hematopoietic system that is caused by heterozygous mutations in RUNX1. FPD/AML patients have a bleeding disorder characterized by thrombocytopenia with reduced platelet numbers and functions, and a tendency to develop AML. No suitable animal models exist for FPD/AML, as Runx1+/-mice and zebra fish do not develop bleeding disorders or leukemia. Here we derived induced pluripotent stem cells(iPSCs) from 2 patientsina family with FPD/AML, and found that the FPD iPSCs display defects in megakaryocytic differentiation in vitro. We corrected the RUNX1 mutation in 1 FPD iPSC line through gene targeting, which led to normalization of megakaryopoiesis of the iPSCs in culture. Our results demonstrate successful in vitro modeling of FPD with patient-specific iPSCs and confirm that RUNX1 mutations are responsible for megakaryopoietic defects in FPD patients.

UR - http://www.scopus.com/inward/record.url?scp=84907215694&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907215694&partnerID=8YFLogxK

U2 - 10.1182/blood-2014-01-550525

DO - 10.1182/blood-2014-01-550525

M3 - Article

VL - 124

SP - 1926

EP - 1930

JO - Blood

JF - Blood

SN - 0006-4971

IS - 12

ER -